Active substance
Benzathine penicillin
- SFDA 3
SFDA Saudi Arabia — SFDA human drug list
| Trade name | Strength | Form · route | Pack | Public price | Type | Company | Status |
|---|---|---|---|---|---|---|---|
| RETARPEN 1.2MEGA U.WITH SOLVENT | 1200000 IU | Powder and solvent for suspension for injection · Intramuscular use | 1 Vial | SAR 6.45 | NCE · Prescription | SANDOZ | Valid |
| RETARPEN 2.4MEGA U. VIAL+SOLVENT | 2400000 IU | Solution · Intramuscular use | 1 Vial | SAR 11.60 | NCE · Prescription | SANDOZ | Withdrawn by MAH · Not Marketed |
| RETARPEN 600000U+ SOLVENT VIAL | 600000 IU | Solution · Intramuscular use | 1 Vial | SAR 3.60 | NCE · Prescription | SANDOZ | Withdrawn by MAH · Not Marketed |
Indications — CHI Daman Drug Formulary
BACTERIAL SKIN INFECTIONS - ERYSIPELAS AND CELLULITIS; BACTERIAL TONSILLOPHARYNGITIS TREATMENT AND PREVENTION; ENDOCARDITIS; MATERNAL AND CHILD HEALTHCARE- PROPHYLAXIS FOR P-PROM, DELIVERY BY C-SECTION, GROUP B STREPTOCOCCUS, SYPHILIS IN PREGNANCY; PHARYNGITIS; SYPHILIS
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.